YD Bio Limited YDES 深 沪
已收盘 04-02 16:00:00 美东时间
7.43
+0.140
+1.92%
华盛通- 最 高7.431
- 今 开7.40
- 成交量 8824股
- 最 低 6.98
- 昨 收 7.29
- 总市值 5.24亿
- 52周最高 25.00
- 市盈率 静 --
- 换手率 0.01%
- 52周最低 5.40
- 委 比 -61.29%
- 总股本 7052.14万
- 历史最高 25.00
- 量 比 0.59
- 振 幅 6.19%
- 历史最低 5.40
- 每 手 1
- 风险率 3.96%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多YD Bio and EG BioMed Jointly Launch Nationwide Telehealth Platform to Accelerate Commercialization of Cancer Detection and Decentralized Clinical Services Across the United States
Taiwanese biotechnology company YD Bio, in collaboration with EG BioMed, has launched the EG Telehealth Platform, marking a significant step in commercializing early cancer detection and clinical services across the U.S. The platform, accessible in 44 states, D.C., and Guam, integrates YD Bio's digital health solutions with EG BioMed's certified diagnostic capabilities, enabling scalable deployment and nationwide patient access. Designed for dece...
03-31 12:00
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers ENvue Medical (NASDAQ:FEED) shares increased by 59.4% to $2.28 during T...
03-25 01:05
Apogee Therapeutics, Tower Semiconductor, Norwegian Cruise Line And Other Big Stocks Moving Higher On Thursday
Stocks fall, Nasdaq drops 200 points. Apogee Therapeutics (APGE) rises 19.4% on positive trial data. Satellogic (SATL), YD Bio (YDES), AXT Inc (AXTI) also see gains.
03-23 22:45
YD Bio Limited CEO Dr. Ethan Shen Details Strategic Roadmap for Integrated Oncology Ecosystem
Taipei, Taiwan, March 17, 2026 (GLOBE NEWSWIRE) - YD Bio Limited, a biotech company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, has outlined its strategic roadmap under CEO Dr. Ethan Shen. The company is moving beyond the traditional single-asset biotech model to build an integrated healthcare ecosystem, synchronizing diagnostic intelligence with advanced therapeutic execution. Key highlights includ...
03-17 12:00
YD Bio's Subsidiary Enters Into Master Strategic Alliance Agreement With YC Biotech To Establish Taiwan-U.S. Dual-Core Regulatory Platform
YD Bio Limited ("YD Bio Ltd" or the "Company") (NASDAQ:YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced that its subsidiary YD Bio
02-25 21:10
YD Bio Limited Enters into Binding Letter of Intent to Acquire Safe Save Medical Cell Sciences & Technology Co., Ltd., Bolstering Leadership in Advanced Immunocell Therapy
YD Bio Ltd entered into a definitive Letter of Intent to acquire Safe Save Medical Cell Sciences & Technology Co., Ltd. (SSMC) for approximately US$26.87 million, combining cash and new shares. SSMC specializes in dendritic cell immunotherapy with its ADCTA technology. The acquisition aims to augment YD Bio's R&D capabilities and expand its presence in cell and gene therapies. The deal, subject to customary closing conditions, is expected to clos...
01-29 13:30
YD Bio Strikes Memorandum Of Understanding To Merge With EG BioMed; Financial Terms Not Disclosed
YD Bio Limited ("YD Bio" or the "Company") (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced that the Company has entered
01-06 22:09
YD Bio Enters into MOU to Merge with EG BioMed, Advancing DNA Methylation–Driven AI Platforms for Cancer Diagnostics and Drug Development
YD Bio Limited has signed a non-binding Memorandum of Understanding (MOU) to merge with EG BioMed, aiming to integrate their DNA methylation-based cancer detection technologies and AI-driven analytics to build a comprehensive oncology platform. The merger could enhance YD Bio's transition into a platform-based biotech company, combining diagnostics, therapeutics, real-world data, and AI for improved cancer detection and treatment. EG BioMed's DNA...
01-06 14:00
YD Bio Announces Latest Plans For New Sites, U.S. Operations Center In California
YD Bio Limited ("YD Bio" or the "Company") (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced initiation of its latest
2025-12-16 22:05
Reported Earlier: YD Bio Through Its Partner 3D Global Biotech, Announces Exovisse Contact Lenses Has Obtained FDA 510(k) Clearance As A Class II Medical Device, Enabling Legal Marketing In The U.S.; Its Exovisse Artificial Tears Have Been Developed In Compliance With The FDA OTC Final Monograph M018
YD Bio Limited ("YD Bio" or the "Company") (NASDAQ:YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced that the Company has reached a
2025-11-25 04:19
